Neoantigen vaccine for Lynch syndrome immune interception
Official title: Assessment of Immune Responses to Neoantigen Vaccination in Lynch Syndrome
Funded at University of Tx Md Anderson Can Ctr · NIH-11223985 · Data updated 2026-11-12
A study to test a vaccine that teaches the immune system to recognize cancer-causing mutations in people with Lynch syndrome.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | July 1, 2026 |
| Project end | June 30, 2031 |
| Funding year | 2026 |
| Award (this year) | $696,924 |
| NIH project number | 1R01CA294638-01A1 |
| Project ID | NIH-11223985 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with Lynch syndrome who carry germline MMR gene mutations and are at high risk for colorectal or endometrial cancer.
✕Less likely to help
Individuals without Lynch syndrome or those who have already developed cancer may not benefit from this vaccine strategy.
What this research studies
Lynch syndrome carriers have a high risk of colorectal and endometrial cancer due to faulty DNA repair and tumor-specific mutations. This project plans to use neoantigen vaccines aimed at shared mutations to stimulate T cells and build long-lasting immune memory in at-risk individuals. Researchers will map common neoantigens and corresponding T cell receptors, then test vaccine-induced immune responses using human samples and appropriate models. The goal is to prevent cancer development by strengthening the body's natural defenses against these mutations.
Why it matters
Potential benefit: If successful, the vaccine could delay or prevent cancers associated with Lynch syndrome by activating protective immune responses.
How similar studies have gone: Preclinical work suggests that neoantigen vaccines can prompt specific T cell responses, but clinical demonstration in Lynch syndrome is needed.
Where this research is happening
-
University of Tx Md Anderson Can Ctr
Houston, United States Active
Researchers
- Principal investigator: Vilar Sanchez, Eduardo — University of Tx Md Anderson Can Ctr
- Study coordinator: Vilar Sanchez, Eduardo
Related research
Other NIH-funded projects on the same topics.
-
Protective dengue vaccines that steer T and B cell responses
A vaccine study aims to guide the body’s T and B cells to fight all four dengue virus types safely and effectively.
-
Respiratory pathogen–specific T cell signatures after vaccination, infection, and treatment
A research effort to map how immune T cells respond to respiratory infections and vaccines, with potential to guide better vaccines and treatments for conditions like covid-19 and pertussis.
-
Malaria vaccine and infection: how the body’s early and later immune responses relate to protection
Researchers are studying how people’s immune systems respond to the malaria pre-erythrocytic stage, whether after vaccination or infection, to identify which responses are linked to protection.
-
Spatially responsive mass vaccination for urban rabies
A new plan uses data and maps to place vaccination sites where they’re most needed in cities, aiming to boost rabies vaccination for both people and dogs.
-
Spatially responsive mass vaccination for urban rabies
A project tests smarter placement of vaccination sites to increase mass canine rabies vaccination in cities.
-
Vaccine failure after Covid-19 vaccination in older adults
This project follows vaccinated older adults to understand who among them still gets Covid-19 and what factors make those outcomes worse.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.